Preferred Label : Alagille syndrome 1;
Symbol : ALGS1;
CISMeF acronym : AHD; ALGS; ALGS1; AWS;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Alagille-watson syndrome; Cholestasis with peripheral pulmonary stenosis; Hepatic ductular hypoplasia, syndromatic; Arteriohepatic dysplasia; AWS; AHD; ALGS; Alagille syndrome;
Description : Alagille syndrome is an autosomal dominant disorder that traditionally has been defined
by a paucity of intrahepatic bile ducts, in association with 5 main clinical abnormalities:
cholestasis, cardiac disease, skeletal abnormalities, ocular abnormalities, and a
characteristic facial phenotype (Li et al., 1997). Cholestasis is a direct consequence
of the paucity of bile ducts. About 39% of patients also have renal involvement, mainly
renal dysplasia (Kamath et al., 2012). Turnpenny and Ellard (2012) reviewed the clinical
features, diagnosis, pathogenesis, and genetics of Alagille syndrome. - Genetic Heterogeneity
of Alagille Syndrome Another form of Alagille syndrome (ALGS2; 610205) is caused by
mutation in the NOTCH2 gene (600275).;
Inheritance : Autosomal dominant;
Molecular basis : Caused by mutation in the jagged 1 gene (JAG1, 601920.0001);
Neoplasia : Hepatocellular carcinoma; Papillary thyroid carcinoma;
Laboratory abnormalities : Increased conjugated bilirubin; Hypercholesterolemia; Hypertriglyceridemia; Elevated transaminases;
Prefixed ID : #118450;
Origin ID : 118450;
UMLS CUI : C1956125;
Automatic exact mappings (from CISMeF team)
Broader ORDO disease(s)
Currated CISMeF NLP mapping
DO Cross reference
False automatic mappings
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT